A patient with plaque-stage mycosis fungoides has successfully been treated with long-term administration of IFN-γ and has been in complete remission for more than 6 years

British Journal of Dermatology

Volumn 134, Issue 1, 1996, Pages 130-133

  Horikoshi, T ^a   Onodera, H ^a   Eguchi, H ^a   Hanada, N ^a   Fukuzawa, K ^a   Takahashi, M ^a   Ishihara, K ^b   Ikeda, S ^c  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b The Japan Foundation   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOGAMMER; CORTICOSTEROID; NIMUSTINE; RECOMBINANT GAMMA INTERFERON; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN TISSUE; MYCOSIS FUNGOIDES; NAUSEA; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

EID: 0030065611     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb07852.x     Document Type: Article

References (19)

1. Edelson RL. Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants. J Am Acad Dermatol 1980; 2: 89-106.
2. Kemme DJ, Bunn PA Jr. State of the art therapy of mycosis fungoides and Sézary syndrome. Oncology 1992; 6: 31-42.
3. Onodera H, Horikoshi T, Miura S et al. Successful treatment of plaque stage mycosis fungoides with recombinant interferon-γ (SUN 4800) alone. Nishinihon Dermatol 1989; 51: 784-88 (in Japanese).
4. Maeda M, Jimbow K, Takahashi M. Association of vesiculobullous eruptions with mycosis fungoides. Dermatologica 1987; 174: 34-8.
5. Vonderheid EC, Scott EJV, Johnson WC et al. Topical chemotherapy and immunotherapy of mycosis fungoides. Arch Dermatol 1977; 113: 454-62.
6. Tanaka S, Oshima T, Ono T et al. Expression in Escherichia coli of chemically synthesized gene for the human immune interferon. Nucleic Acids Res 1983; 11: 1707-23.
7. Herberman RB. Interferon and cytotoxic effector cells. In: Interferon II. Interferon and the Immune System (Vilcek J, De Maeyer E, eds). Amsterdam: Elsevier, 1984; 61.
8. Rook AH, Vowels BR, Jaworsky C et al. The immunopathogenesis of cutaneous T-cell lymphoma. Arch Dermatol 1991; 129: 486-9.
9. Mosmann TR, Cherwinski H, Bond MW et al. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-57.
10. Dummer R, Kohl O, Gillessen J et al. Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Arch Dermatol 1993; 129: 433-6.
11. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th-2 cells. J Invest Dermatol 1992; 99: 90-4.
12. + human T cells. J Immunol 1991; 146: 4209-14.
13. Vercelli D, Jabara HH, Lauener RP, Geha RS. IL-4 inhibits the synthesis of INF-γ and induces the synthesis of IgE in human mixed lymphocyte cultures. J Immunol 1990; 144: 570-3.
14. Peleman BR, Wu J, Rargeas C, Delespesse G. Recombinant interleukin 4 suppresses the production of interferon γ by human mononuclear cells. J Exp Med 1989; 170: 1751-6.
15. Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170: 827-45.
16. Manetti R, Parronchi P, Giudizi MG et al. Natural killer cell stimulatory factor (NKSF/IL-12) induces Th1-type specific immune responses and inhibits the development of IL-4 producing Th cells. J Exp Med 1993; 177: 1199-204.
17. Rook AH, Kubin M, Vonderheid EC et al. Interleukin-12 (IL-12) reverses cytokine and immune abnormalities of Sézary syndrome. J Invest Dermatol 1994; 102: 557.
18. D'Andrea A, Aste-Amezaga M, Valiante NM et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-8.
19. Kaplan EH, Rosen ST, Norris DB et al. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82: 208-12.